Vanguard Group’s Lucid Diagnostics LUCD Stock Holding History

Vanguard Group’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.42M	Buy	4,968,608 +444,611	+10%	+$497K	﹤0.01%	3221
2025 Q3	$4.57M	Buy	4,523,997 +396,719	+10%	+$433K	﹤0.01%	3307
2025 Q2	$4.75M	Buy	4,127,278 +3,238,404	+364%	+$4.18M	﹤0.01%	3235
2025 Q1	$1.32M	Buy	888,874 +327,959	+58%	+$394K	﹤0.01%	3628
2024 Q4	$459K	Hold	560,915	–	–	﹤0.01%	3969
2024 Q3	$457K	Hold	560,915	–	–	﹤0.01%	3993
2024 Q2	$460K	Hold	560,915	–	–	﹤0.01%	4032
2024 Q1	$454K	Buy	560,915 +228,524	+69%	+$297K	﹤0.01%	4041
2023 Q4	$469K	Buy	332,391 +6,825	+2%	+$9K	﹤0.01%	4049
2023 Q3	$381K	Buy	325,566 +5,733	+2%	+$8.32K	﹤0.01%	4131
2023 Q2	$445K	Buy	319,833 +400	+0.1%	+$603	﹤0.01%	4151
2023 Q1	$447K	Hold	319,433	–	–	﹤0.01%	4151
2022 Q4	$434K	Buy	319,433 +67	+0%	+$121	﹤0.01%	4139
2022 Q3	$489K	Buy	319,366 +32,305	+11%	+$80.4K	﹤0.01%	4214
2022 Q2	$649K	Sell	287,061 -25,815	-8%	-$57.4K	﹤0.01%	4218
2022 Q1	$1.05M	Buy	312,876 +63,687	+26%	+$233K	﹤0.01%	4190
2021 Q4	$1.34M	Buy	+249,189	New	+$2.02M	﹤0.01%	4175

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's LUCD Position: Q4 2025 in Review

Vanguard Group increased its Lucid Diagnostics (LUCD) stake by 9.8% in Q4 2025, buying an estimated $497K and bringing the position to 4,968,608 shares worth $5.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Vanguard Group first reported a position in LUCD in Q4 2021 and has held it in 17 quarters since. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

Vanguard Group held 4,968,608 shares of Lucid Diagnostics worth $5.42M as of Q4 2025.
Vanguard Group bought 444,611 Lucid Diagnostics shares in Q4 2025, an estimated $497K.
Lucid Diagnostics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3221 holding.
Vanguard Group first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 17 quarters since.
89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.